EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

38476 reported adverse events

Drug classes: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE:

#	Side effect	Count
0	BONE DENSITY DECREASED	13877
1	CHRONIC KIDNEY DISEASE	8346
2	OSTEONECROSIS	7646
3	BONE LOSS	7522
4	RENAL INJURY	7396
5	RENAL FAILURE	7184
6	MULTIPLE FRACTURES	6805
7	SKELETAL INJURY	6594
8	TOOTH LOSS	6543
9	OSTEOPOROSIS	6034

See all common reactions for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	SKELETAL INJURY	6594	0.6961
1	BONE DEMINERALISATION	283	0.6345
2	BONE LOSS	7522	0.6328
3	BONE DENSITY DECREASED	13877	0.5252
4	TOOTH INJURY	1623	0.5202
5	MULTIPLE FRACTURES	6805	0.5067
6	CLOACAL EXSTROPHY	25	0.4630
7	ACUTE HIV INFECTION	77	0.4118
8	BLADDER AGENESIS	26	0.4000
9	TOOTH LOSS	6543	0.3966

See all enriched reactions for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE